Publication date: Jun 01, 2025
We evaluated homologous neutralizing antibody (NtAb) and T-cell responses after receipt of a JN. 1-adapted mRNA vaccine in a mixed population comprising healthy controls (HC) (n = 15), end-stage chronic kidney disease (CKD) patients (n = 17), and allogeneic hematopoietic stem cell transplant recipients (allo-HCT) (n = 13). Most participants (42/45) were SARS-CoV-2-experienced at the time of immunological testing. JN. 1-spike-binding NtAbs were measured with a vesicular stomatitis virus pseudotype-based neutralization assay, whereas interferon (IFN)-γ-producing spike-directed CD4 or CD8 T-cell frequencies were enumerated using flow cytometry for intracellular staining. All participants had detectable JN. 1 NtAbs at baseline; overall, JN. 1-NtAb levels increased in HC (median, ∼1 log; p
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | cell |
| disease | MESH | chronic kidney disease |
| disease | IDO | assay |
| disease | MESH | COVID-19 |
| disease | MESH | Immunocompromised Host |